Benazepril affects integrin-linked kinase and smooth muscle α-actin expression in diabetic rat glomerulus and cultured mesangial cells

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Niu, Honglin ^a,b   Nie, Lei ^c,d   Liu, Maodong ^a,b   Chi, Yanqing ^a,b   Zhang, Tao ^a,b   Li, Ying ^a,b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Key Laboratory of Kidney Diseases of Hebei Province   (China)

^c YALE UNIVERSITY   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Benazepril; Diabetic nephropathy; Glomerular mesangial cells; Integrin linked kinase; Smooth muscle actin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; BENAZEPRIL; GLUCOSE; INTEGRIN LINKED KINASE; MESSENGER RNA; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA1; ACTIN; BENZAZEPINE DERIVATIVE; INTEGRIN-LINKED KINASE; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BORDERLINE HYPERTENSION; CELL CULTURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GLOMERULUS; GLUCOSE BLOOD LEVEL; HISTOLOGY; KIDNEY PARENCHYMA; MALE; MESANGIUM CELL; NONHUMAN; PATHOGENESIS; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; RENAL PROTECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DIABETES MELLITUS, EXPERIMENTAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ACTINS; ANIMALS; BENZAZEPINES; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; GENE EXPRESSION REGULATION; KIDNEY GLOMERULUS; MALE; MESANGIAL CELLS; MUSCLE, SMOOTH; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84906924939     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-135     Document Type: Article

References (35)

1. Clinical practice. Nephropathy in patients with type 2 diabetes. Remuzzi G, Schieppati A, Ruggenenti P, N Engl J Med 2002 346 15 1145 1151 10.1056/NEJMcp011773 11948275
2. Pathophysiology of diabetic nephropathy. Sego S, Nephrol Nurs J 2007 34 6 631 633 18203571
3. Diabetic nephropathy: mechanisms of renal disease progression. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR, Exp Biol Med (Maywood) 2008 233 1 4 11 10.3181/0705-MR-134 18156300
4. TGF-beta1-induced PINCH-1-ILK-alpha-parvin complex formation regulates mesangial cell proliferation and hypertrophy. Kim SM, Kim N, Lee S, Kim do K, Lee YM, Ahn SH, Song JH, Choi BK, Wu C, Jung KY, Exp Mol Med 2007 39 4 514 523 10.1038/emm.2007.57 17934340
5. The distribution and regulation of integrin-linked kinase in normal and diabetic kidneys. Guo L, Sanders PW, Woods A, Wu C, Am J Pathol 2001 159 5 1735 1742 10.1016/S0002-9440(10)63020-9 11696434
6. Expression of alpha-smooth muscle actin in the developing kidney vasculature. Carey AV, Carey RM, Gomez RA, Hypertension 1992 19 2 Suppl I168 175 1735573
7. Beneficial effect of all-trans retinoic acid (ATRA) on glomerulosclerosis rats via the down-regulation of the expression of alpha-smooth muscle actin: a comparative study between ATRA and benazepril. Hu P, Qin YH, Pei J, Lei FY, Hu B, Lu L, Exp Mol Pathol 2010 89 1 51 57 10.1016/j.yexmp.2010.05.003 20493835
8. Chronic renal failure: pathophysiology. Jacobson HR, Lancet 1991 338 8764 419 423 10.1016/0140-6736(91)91042-S 1678092
9. Role of angiotensin II in diabetic nephropathy. Leehey DJ, Singh AK, Alavi N, Singh R, Kidney Int Suppl 2000 77 93 98 10997697
10. Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy. Border WA, Noble NA, Kidney Int 1998 54 4 1390 1391 10.1046/j.1523-1755.1998.00127.x 9773681
11. Diabetic nephropathy: prevention and treatment. Parving HH, Kidney Int 2001 60 5 2041 2055 10.1046/j.1523-1755.2001.00020.x 11703631
12. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy. Jacobsen P, Rossing K, Parving HH, Curr Opin Nephrol Hypertens 2004 13 3 319 324 10.1097/00041552-200405000-00009 15073491
13. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P, N Engl J Med 1996 334 15 939 945 10.1056/NEJM199604113341502 8596594
14. NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Satoh M, Fujimoto S, Haruna Y, Arakawa S, Horike H, Komai N, Sasaki T, Tsujioka K, Makino H, Kashihara N, Am J Physiol Renal Physiol 2005 288 6 1144 1152 10.1152/ajprenal.00221.2004 15687247
15. Measurement of invasive blood pressure in rats. Parasuraman S, Raveendran R, J Pharmacol Pharmacother 2012 3 2 172 177 22629093
16. Alagebrium reduces glomerular fibrogenesis and inflammation beyond preventing RAGE activation in diabetic apolipoprotein E knockout mice. Watson AM, Gray SP, Jiaze L, Soro-Paavonen A, Wong B, Cooper ME, Bierhaus A, Pickering R, Tikellis C, Tsorotes D, Thomas MC, Jandeleit-Dahm KA, Diabetes 2012 61 8 2105 2113 10.2337/db11-1546 22698914
17. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. Okuda S, Languino LR, Ruoslahti E, Border WA, J Clin Invest 1990 86 2 453 462 10.1172/JCI114731 2200803
18. Gremlin induces cell proliferation and extra cellular matrix accumulation in mouse mesangial cells exposed to high glucose via the ERK1/2 pathway. Huang H, Li Y, Liu M, Shi Y, Zhang T, BMC Nephrol 2013 14 33 1471 2369
19. Transforming growth factor-beta in disease: the dark side of tissue repair. Border WA, Ruoslahti E, J Clin Invest 1992 90 1 1 7 10.1172/JCI115821 1634602
20. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. Sheetz MJ, King GL, Jama 2002 288 20 2579 2588 10.1001/jama.288.20.2579 12444865
21. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim MA, Am J Physiol Renal Physiol 2004 286 6 1039 1045 10.1152/ajprenal.00371.2003 14722017
22. Involvement of the platelet-derived growth factor receptor in angiotensin II-induced activation of extracellular regulated kinases 1 and 2 in human mesangial cells. Mondorf UF, Geiger H, Herrero M, Zeuzem S, Piiper A, FEBS Lett 2000 472 1 129 132 10.1016/S0014-5793(00)01433-2 10781819
23. Physical factors and glomerulosclerosis. Cause or coincidence? Wesson LG, Nephron 1998 78 2 125 130 10.1159/000044899 9496726
24. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. Lopez-Novoa JM, Rodriguez-Pena AB, Ortiz A, Martinez-Salgado C, Lopez Hernandez FJ, J Transl Med 2011 9 13 10.1186/1479-5876-9-13 21251296
25. High glucose-induced TGF-beta 1 regulates mesangial production of heparan sulfate proteoglycan. Kolm V, Sauer U, Olgemoller B, Schleicher ED, Am J Physiol 1996 270 5 Pt 2 812 821 8928843
26. Sequential effects of high glucose on mesangial cell transforming growth factor-beta 1 and fibronectin synthesis. Oh JH, Ha H, Yu MR, Lee HB, Kidney Int 1998 54 6 1872 1878 10.1046/j.1523-1755.1998.00193.x 9853252
27. Integrin-linked kinase in renal disease: connecting cell-matrix interaction to the cytoskeleton. Blattner SM, Kretzler M, Curr Opin Nephrol Hypertens 2005 14 4 404 410 10.1097/01.mnh.0000172730.67746.5b 15931012
28. Expression of cytoskeletal proteins during the course of experimental diabetic nephropathy. Sanai T, Sobka T, Johnson T, el-Essawy M, Muchaneta-Kubara EC, Ben Gharbia O, el Oldroyd S, Nahas AM, Diabetologia 2000 43 1 91 100 10.1007/s001250050012 10663221
29. The immunomodulator FTY720 and its phosphorylated derivative activate the Smad signalling cascade and upregulate connective tissue growth factor and collagen type IV expression in renal mesangial cells. Xin C, Ren S, Eberhardt W, Pfeilschifter J, Huwiler A, Br J Pharmacol 2006 147 2 164 174 10.1038/sj.bjp.0706452 16299553
30. Angiotensin II and its receptors in the diabetic kidney. Burns KD, Am J Kidney Dis 2000 36 3 449 467 10.1053/ajkd.2000.16192 10977776
31. Mechanisms of mitogen-activated protein kinase activation in experimental diabetes. Awazu M, Ishikura K, Hida M, Hoshiya M, J Am Soc Nephrol 1999 10 4 738 745 10203357
32. Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Haneda M, Araki S, Togawa M, Sugimoto T, Isono M, Kikkawa R, Diabetes 1997 46 5 847 853 10.2337/diab.46.5.847 9133554
33. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S, Proc Natl Acad Sci U S A 1998 95 19 11211 11216 10.1073/pnas.95.19.11211 9736715
34. PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. Remy I, Montmarquette A, Michnick SW, Nat Cell Biol 2004 6 4 358 365 10.1038/ncb1113 15048128
35. Efficacy and safety of benazepril for advanced chronic renal insufficiency. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW, N Engl J Med 2006 354 2 131 140 10.1056/NEJMoa053107 16407508